Zobrazeno 1 - 10
of 63
pro vyhledávání: '"R. Stigliano"'
Autor:
Raffaella Viganò, D. Angrisani, Chiara Mazzarelli, A. Panariello, R. Stigliano, P. Prandoni, Luca S. Belli, S. De Nicola, Andrea Airoldi, M. Vangeli, M. Percudani, Giovanni Perricone
Publikováno v:
Digestive and Liver Disease. 52:e68-e69
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumor with a five-year survival of less than 6%. Chronic pancreatitis (CP), an inflammatory process in of the pancreas, is a strong risk factor for PDAC. Several genetic polymorphisms have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::82d06ad3acbf5a3eeaa270d21d92da33
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086509
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086509
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Cancer Treatment Reviews. 33:437-447
Summary Background : Tumour biopsy is usually considered mandatory for patient management by oncologists. Currently percutaneous ablation is used therapeutically for cirrhotic patients with small hepatocellular carcinoma (HCC), not suitable for resec
Autor:
Tim Meyer, Marco Senzolo, Evangelos Cholongitas, Christos Triantos, Neil Davies, J. Tibballs, Andrew K. Burroughs, Laura Marelli, David Patch, R. Stigliano
Publikováno v:
CardioVascular and Interventional Radiology. 30:6-25
Chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, or whether embolization (TAE) alone gives the same survival advantage, is not known.To evaluate whether specific patient chara
Autor:
Filomena Morisco, Hugo Martines, Amar P. Dhillon, Keith Rolles, Andrew K. Burroughs, David Patch, R. Stigliano, Brian R. Davidson, Alessandro Grasso, Alberto Quaglia
Publikováno v:
Transplantation. 81:1532-1541
Background. Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) remains a major cause of post-LT death. Methods. To assess which preoperative and postoperative variables were related to recurrence of HCC after LT in patients
Autor:
Andrew K. Burroughs, R. Stigliano
Publikováno v:
Journal of Hepatology. 43:563-568
Liver transplantation (LT) is curative therapy in selected cases of hepatocellular carcinoma (HCC), as it removes both the tumour and the premalignant cirrhotic liver [1–3]. In Europe, 10% of LT were performed for HCC from 1988 to 1997 [4]. Two gro
Autor:
David Patch, Christos Triantos, Ulrich Thalheimer, Andrew K. Burroughs, R. Stigliano, Dimitrios Samonakis
Publikováno v:
Transplantation. 79:261-268
Antiviral therapy for recurrent hepatitis C after liver transplantation is increasingly used. This systematic review presents both viral and histological response in three areas: pretransplant (5 studies/180 patients), preemptive therapy soon after t
Autor:
John R. Buscombe, Neil M Davies, Andrew K. Burroughs, David Patch, Tim Meyer, Vibhakorn Shusang, Evangelos Cholongitas, Laura Marelli, J. Tibballs, R. Stigliano
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 50(6)
Transarterial chemoembolization (TACE) improves survival in patients with hepatocellular carcinoma (HCC) in whom curative therapies are not suitable. The aim of this study was to assess survival differences in patients with hepatic cirrhosis and unre
Autor:
Laura Marelli, R. Stigliano, Hugo Martines, David Patch, Keith Rolles, A. Grasso, AP Dhillon, Brian R. Davidson, A.K. Burroughs, M. Pleguezuelo, Dinesh K. Sharma
Publikováno v:
Annals of surgical oncology. 15(12)
A new prognostic score including tumour differentiation--establishing two groups of patients: group A with3 points and group B with4 points--improved the accuracy of the Milan criteria in predicting recurrence of hepatocellular carcinoma (HCC) after